• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Radiol . 2 Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients

tetano

Editor, Senior Moderator
Eur J Radiol


. 2021 Mar 20;138:109676.
doi: 10.1016/j.ejrad.2021.109676. Online ahead of print.
Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients


Maurizio Balbi[SUP] 1 [/SUP], Caterina Conti[SUP] 2 [/SUP], Gianluca Imeri[SUP] 2 [/SUP], Anna Caroli[SUP] 3 [/SUP], Alessandra Surace[SUP] 4 [/SUP], Andrea Corsi[SUP] 4 [/SUP], Elisa Mercanzin[SUP] 4 [/SUP], Alberto Arrigoni[SUP] 5 [/SUP], Giulia Villa[SUP] 3 [/SUP], Fabiano Di Marco[SUP] 6 [/SUP], Pietro Andrea Bonaffini[SUP] 4 [/SUP], Sandro Sironi[SUP] 4 [/SUP]



Affiliations

Abstract

Purpose: To evaluate chest computed tomography (CT) and pulmonary function test (PFT) findings in severe COVID-19 patients after discharge and correlate CT pulmonary involvement with PFT results.
Methods: COVID-19 patients admitted to our hospital between February 25 and May 2, 2020, were retrospectively included according to the following criteria: (a) COVID-19 defined as severe based on the WHO interim guidance (i.e., clinical signs of pneumonia plus respiratory rate > 30 breaths/min, severe respiratory distress, and/or SpO[SUB]2[/SUB] < 90 % on room air); (b) chest radiograph in the acute setting; (c) post-discharge unenhanced chest CT; and (d) post-discharge comprehensive PFT. Imaging findings were retrospectively evaluated in consensus by two readers, and volume of abnormal lung was measured on CT using 3D Slicer software. Differences between demographics, comorbidities, acute radiographic findings, PFT, and post-discharge clinical and laboratory data of patients with normal and abnormal CT findings were assessed by Mann-Whitney or Fisher tests, and the compromised lung volume-PFT association by Pearson correlation after removing possible outliers.
Results: At a median of 105 days from symptom onset, 74/91 (81 %) patients had CT abnormalities. The most common CT pattern was combined ground-glass opacity and reticular pattern (46/74, 62 %) along with architectural distortion (68/74, 92 %) and bronchial dilatation (66/74, 89 %). Compromised lung volume had a median value of 15 % [11-23], was higher in dyspneic patients, and negatively correlated with the percentage of predicted DLCO, VA, and FVC values (r = -0.39, -0.5, and -0.42, respectively). These PFT parameters were significantly lower in patients with CT abnormalities. Impairment of DLCO and KCO was found in 12 (13 %) cases, possibly implying an underlying pulmonary vasculopathy in this subgroup of patients.
Conclusions: Most severe COVID-19 survivors still had physiologically relevant CT abnormalities about three months after the disease onset, with an impairment of diffusion capacity on PFT. A pulmonary vasculopathy was suggested in a minor proportion of patients.

Keywords: COVID-19; Lung diseases; Respiratory function tests; Severe acute respiratory syndrome coronavirus 2; Survivors; Tomography.
 
Back
Top Bottom